Long-term ovarian cancer data reinforces Lynparza benefit

Long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of Lynparza (Olaparib), with or without bevacizumab, have demonstrated clinically-meaningful improvements in overall survival (OS).

The data were presented at the 2022 European Society of Medical Oncology (ESMO) and published in Journal of Clinical Oncology, with further results showing class-leading progression-free survival in combination with bevacizumab for homologous recombination deficiency (HRD)-positive patients, versus active comparator, bevacizumab, and as monotherapy for patients with BRCA mutations, versus placebo, respectively.

"A targeted treatment in the first-line maintenance setting is critical to helping them live longer"Both trials which were conducted in biomarker-selected, newly diagnosed patients with advanced ovarian cancer in the first-line maintenance setting also demonstrated a consistent safety profile.